Electrophysiological Investigations of Prion Protein Roles in Health and Disease by Foliaki, Simote T. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







of Prion Protein Roles in Health 
and Disease
Simote T. Foliaki, Bradley R. Groveman and Cathryn L. Haigh
Abstract
Prion diseases are transmissible and fatal neurological disorders associated 
with the misfolding of cellular prion protein (PrPC) into disease-causing isoforms 
(PrPD) in the central nervous system. The diseases have three etiologies; acquired 
through exposure to the infectious PrPD, sporadic, arising from no known cause, 
and hereditary due to familial mutations within the PRNP gene. The manifesta-
tion of clinical signs is associated with the disruption of neuronal activity and 
subsequent degeneration of neurons. To generate insight into the mechanisms by 
which neuronal activity becomes disrupted in prion diseases, electrophysiological 
techniques have been applied to closely study the electrical signaling proper-
ties of neurons that lack functional PrPC as well as neurons that are developing 
pathological features of prion diseases due to infection or genetic mutation. In this 
review, we will compile the electrophysiological evidences of neurophysiological 
roles of PrPC, how those roles are changed in neurons that are developing prion 
diseases, and how disease-associated effects are exacerbated during the clinical 
stage of disease.
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1. Introduction
Prion diseases are transmissible neurological disorders that are always fatal 
following symptom onset. These diseases affect humans and animals. The most 
common forms in humans are Creutzfeldt-Jakob disease (CJD), Gerstmann-
Straussler-Scheinker syndrome (GSS), and familial fatal insomnia (FFI). The 
primary causative event is the misfolding of PrPC into PrPD in the central nervous 
system, which is followed by progressive impairments of cognition and behaviour. 
The fundamental roots of the clinical manifestations are the impairments of neuro-
nal activity. In patients, these changes are mostly detected by electroencephalogra-
phy (EEG) and functional magnetic resonance imaging (fMRI) [1]. The abnormal 
neuronal activities associated with prion diseases have been successfully modeled in 
the laboratory using mouse models, cultured mouse primary neurons, and cultured 
human/mouse induced pluripotent stem cells [2, 3]. As a result of advancements in 
experimental neuro-electrophysiology technologies, our understanding of neuro-
electrical signaling dysfunctions associated with prion diseases has substantially 
improved over the last decades.
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In experimental models, there have been several neuro-electrophysiological 
phenomena identified in the glutamatergic neuronal system that closely correlate 
with the underlying molecular mechanisms of memory formation/loss and behav-
ioral change. These include the short-term plasticity (STP), long-term potentiation 
(LTP), and long-term depression (LTD) [4]. STP is usually detected as a rapid 
physiological alteration of neuronal activity that lasts milliseconds to seconds 
immediately after neurons receiving a stimulation [5, 6]. This short-term function 
is usually due to a rapid enhanced release of neurotransmitters that overwhelmingly 
activate the preexisting receptors on the post-synaptic terminals [5, 6]. Through 
such a mechanism, STP can be evoked by a paired-stimulus delivered a few mil-
liseconds apart, in which the post-synaptic response evoked by the second stimulus 
indicates the probability of neurotransmitter release at a synapse or a population of 
synapses [5, 6]. Further, with repetitive short (~0.5–1 min) trains of high frequency 
(~100–200 Hz) stimulation, neurotransmitters are released at a substantial level, 
which extensively depolarizes the post-synaptic membrane causing activation of 
the NMDA receptor (NMDAR), a glutamate receptor that modulates the post-syn-
aptic currents when it is active [7]. The post-synaptic response within seconds of 
the high frequency stimulation is largely STP, reflecting the levels of neurotransmit-
ters release [8]. Repetitive stimuli can also evoke a short-term phenomenon called 
the afterhyperpolarization, which usually lasts 1 second. Afterhyperpolarization 
is divided into three parts, the fast (first few milliseconds), medium (100–500 
milliseconds), and slow (longer than 500 milliseconds) afterhyperpolarization [9]. 
The afterhyperpolarization is largely dependent on the activity of potassium chan-
nels, especially the calcium-sensitive potassium channels, as well as the activity of 
voltage-gated calcium channels and the level of intracellular calcium [9, 10].
The activation of NMDARs following a repetitive high frequency stimula-
tion causes externalization of more AMPA receptors (AMPARs). AMPARs are 
a type of glutamate receptor known as the workhorse of glutamatergic neurons 
because they can rapidly generate synaptic signaling [7]. The rapid recruitment 
of AMPARs can subsequently activate neighboring silent synapses, causing 
excitatory neurons to remain persistently active for hours, a phenomenon called 
LTP [11]. On the other hand, repetitive and prolonged (~5–10 min) trains of 
low frequency (~0.5–5 Hz) stimulation cause depolarization of post-synaptic 
membrane and activation of NMDARs in a way that triggers internalization of 
AMPARs, causing depression of the post-synaptic current that can persist for 
hours, a neuro-phenomenon called LTD [4]. While these are the main known 
mechanisms of LTP and LTD, the fast-growing interest on how these phenomena 
are induced and maintained has led to the discovery of a wide variety of potential 
molecular mechanisms.
To understand the mechanisms underlying the neuronal dysfunctions associated 
with the clinical phenotypes of prion diseases, studies have focused on identifying 
how the neuro-electrophysiological correlates of cognition and behaviour become 
impaired in experimental models of disease. In this review, we will discuss the nor-
mal neuro-electrophysiological roles of PrPC and the neuro-physiological altera-
tions during the asymptomatic stage to the early onset of clinical signs in models of 
acquired and genetic prion diseases.
2. Neuro-electrophysiology of PrPC
PrPC is a membrane-tethered glycoprotein, targeted to the outer leaflet of the 
plasma-membrane by a glycosylphosphadiylinositol (GPI) anchor. The precise 
functions of PrPC in the central nervous system are largely unknown; however, 
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there is considerable evidence to suggest that PrPC has important roles in neuro-
nal activity [12] (Table 1). These putative functions of PrPC have been studied 
by combinations of electrophysiological recordings, genetic modifications, and 
pharmacological approaches.
2.1 PrPC assists synaptic transmission
PrPC is expressed in both pre- and postsynaptic terminals [13–19], where it 
plays essential roles in synaptic activity. PrPC interacts with presynaptic vesicles 
and facilitates release of neurotransmitters [13, 20, 21]. PrPC also regulates presyn-
aptic calcium channels, allowing influx of sufficient calcium into the presynaptic 
terminal to facilitate the release of neurotransmitters [21, 22]. At the post-synaptic 
terminals, PrPC interacts with various post-synaptic glutamate receptors and 
regulates their functions (discussed later in this section) [14, 23]. In mice devoid 
of PrPC expression, it has been found that LTP within the hippocampal CA1 and 
dentate gyrus is significantly impaired [24–26]. This impairment is associated with 
memory and behavioral deficits [27]. However, this is still a point of contention 
as normal LTP within these regions has also been observed and the discrepancy 
appears un-related to the genetic background of the mouse model [5, 28–30]. 
Hippocampal CA1 metaplasticity is also impaired in PrP knockout mice; here the 
post-synaptic responses become enhanced as opposed to being depressed when a 
low frequency stimulation is paired with a couple trains of theta-burst stimulation 
(consists of 10 trains delivered at 5 Hz where each train comprises of 4 pulses deliv-
ered at 100 Hz) at an interval of ~25 minutes [29]. Further, Juvenile PrP knockout 
mice exhibit poor sensorimotor performance, which correlates with the cerebellar 
granule cells displaying slow rate of inward and outward membrane currents, slow 
kinetics of excitatory post-synaptic responses, and incompetence to induce LTP by 
theta-bust stimulation [31]. These abnormal phenotypes disappear when the mice 
reach adulthood [30, 31], thus suggesting that PrPC plays some essential roles in 
synaptic transmission during early development.
Roles of PrPC in cell functions and signaling Reference




Calcium-dependent potassium channel function [20, 22, 30]
L-type voltage-gated potassium channel function [10, 20]
NMDA receptor function [14]
Voltage-gated calcium channel function [36]
Calcium homeostasis [10, 20]
GABA receptor function [14, 22, 
30, 38]
Maintenance of peripheral nerves myelination [40]
Modulator of various signaling functions including Fyn and mGluR5 dependent regulation 
of NMDAR activity, and modulation of p38 Mitogen Activated Protein Kinase signaling 
pathway (refer to the subheading: PrPC regulates major intracellular signaling pathways)
[33, 42]
Table 1. 
Summary of the normal physiological roles of PrPC including the studies that reported those roles.
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2.2 GPI-anchored PrPC regulates ion channels activity
The activity of ion channels is essential for the maintenance of synaptic func-
tions [7]. The involvement of PrPC in ion channel activity has been implicated in 
mice lacking PrPC [12]. These mice exhibit electrophysiological features of dys-
functional ion channels such as reduced slow and medium afterhyperpolarization in 
the hippocampal CA1 region, which indicates an impairment of calcium-dependent 
K+ channels [22, 24, 32]. This finding is consistent with the report that PrPC 
modulates the activity of voltage-dependent potassium channels [33]. Additionally, 
the hippocampal CA1 exhibits reduced currents of L-type voltage-gated calcium 
channels in the absence of PrPC [22], albeit another study showed the contradic-
tory finding [10]. In cultured hippocampal neurons from PrP knockout mice, the 
activity of NMDARs is significantly impaired. These receptors exhibit a longer 
decay time and larger amplitude of miniature synaptic currents as well as very slow 
deactivation kinetics of agonist-mediated currents [14]. The interpretation of these 
findings was that PrPC functions to prevent hyperactivation of NMDARs.
The contribution of PrPC to ion channel activity has also been reported in a 
variety of cells expressing PrPC with various primary sequence mutations; designed 
to determine the effect of each mutant on ion channel activity as a measure of 
prion neurotoxicity [34]. Several deletions (between residues 94 and 134) in the 
charged and hydrophobic region of PrP, a conserved region of PrP, cause dysfunc-
tion of cation-permeable channels, which increases the inward currents leading 
to cellular toxicity and cell death [34–36]. The deletion of PrP residues 105–125 or 
94–134 causes the most deleterious dysfunction of ion channels. Deletion of other 
residues such as PrP 94–110, 111–134, and 114–121 also causes similar toxic effect, 
but at relatively lower degrees [35]. Although these observations have mostly been 
reported in nonneuronal cells (HEK293T) [34–36], the neonatal death in mice 
expressing PrP devoid of 105–125 residues affirms that the deleterious effect of this 
deletion appears independent of cell type [37].
When PrP residues 105–125 are co-deleted with residues 51–90 (a five octa-
peptide repeat region), the impairment of ion channels becomes slightly reduced 
[35]. Furthermore, the toxic effect of PrP lacking residues 105–125 vanishes when 
co-deleted with either the GPI anchor (PrP 231–254) alone or the GPI anchor and 
the endogenous signal motif (PrP 1–22; to retain PrP in the cytoplasm), suggest-
ing that the toxic PrP needs to be transported out of the cytoplasm and anchored 
to the lipids in order to disrupt the activity of ion channels. This evidence implies 
that GPI-anchored PrPC prevents hyperactivity of ion channels. Further sup-
port for this role has also been observed using cells lacking GPI-anchored PrP, 
where the calcium current intensity of voltage-gated calcium channels (contain-
ing subunits CaV2.1/β and α2δ-1 or α2δ-2) becomes reduced in the presence of 
GPI-anchored PrP but enhanced in the presence of only GPI-anchorless PrP [38]. 
Taken together, when PrPC is correctly trafficked and anchored to the cell mem-
brane, it regulates the activity of ion channels, predominantly through its charged 
and hydrophobic region.
2.3 PrPC maintains neuronal calcium homeostasis
As aforementioned, PrPC regulates ion channels including the voltage-gated 
calcium channels and NMDARs. In the absence of endogenous PrPC expression, 
hippocampal CA1 neurons exhibit dysfunction of calcium homeostasis associated 
with diminished currents of Nifedipine-sensitive voltage-gated L-type calcium-
channels [22]. This finding contradicts another showing that voltage-gated calcium 
channels are not affected in PrP knockout hippocampal neurons despite exhibiting 
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impaired slow afterhyperpolarization, suggesting that the disruption of calcium 
homeostasis is less likely to be due to a dysfunction or loss of voltage-gated calcium 
channels [10]. In a study by Powell et al., they revealed that the calcium uptake into 
the ER, a calcium storage mechanism essential for normal cellular calcium homeo-
stasis, was abnormally enhanced in PrP knockout neurons [10]. This dysfunction, 
together with the reduced amplitude of slow afterhyperpolarization, was signifi-
cantly rescued following pharmacological inhibition of the sarcoplasmic/ER pump 
calcium-ATPase [10]. Together, these data suggest that PrPC regulates intracellular 
calcium homeostasis largely by controlling ER calcium uptake, which subsequently 
alters the activity of voltage gated calcium channels.
2.4 PrPC regulates function of inhibitory neurons
Mice devoid of PrPC expression exhibit weak GABA(A) receptor-mediated fast 
inhibition in the hippocampal CA1 region [24]. The inhibiting role of GABAergic 
neurons in the glutamatergic transmission is important to ensure no hyperactiv-
ity of the excitatory neurons [39]. This weak GABAergic neuronal activity in 
the absence of PrPC is consistent with other reports of enhanced excitability 
in the hippocampal CA1 and dentate gyrus of PrP knockout mice [14, 32, 40]. 
Importantly, the hyperactivity of excitatory neurons together with the weak 
function of GABA(A) receptor agrees with the report that PrP knockout mice 
are susceptible to kainite-induced epileptic seizure [40]. However, a study of the 
olfactory bulb in PrPC lacking mice has shown an enhanced inhibitory postsynaptic 
currents are received by mitral cells, which appears associated with the depressed 
high-frequency oscillations during a single breath [41]. Altogether, PrPC appears to 
differentially regulate inhibitory neuronal activity based on location; where in the 
hippocampus it enhances the inhibitory activity to prevent excitotoxic death, the 
olfactory bulb it prevents hyperactivity of the inhibitory cells to maintain normal 
high frequency oscillations [41].
2.5 PrPC maintains myelination of nerve cells
One of the abnormalities detected in mice lacking PrPC expression is the 
demyelination of peripheral nerve cells [42]. The loss of PrPC in neurons, but not in 
Schwann cells, triggers chronic demyelination, which causes significant reduction 
in peripheral nerve conduction velocity [42]. This dysfunction can be prevented by 
re-introduction of PrPC expression as well as by activation of PrPC proteolysis [42], 
thus indicates that PrPC is necessary for maintaining the integrity of myelin sheath. 
This finding helps consolidating locomotion deficits such as reduced capability 
to explore an open field, nest, swim, and groom, which have been reported in 
aged PrP knockout mice [27, 43]. However, it is not yet known whether PrPC also 
displays this function in the central nervous system.
2.6 PrPC regulates major intracellular signaling pathways
PrPC anchoring to the cell membrane is thought to be essential for its role in 
signaling functions [35, 44]. Several downstream signaling pathways of PrPC have 
been identified following the discovery of its role as a receptor in neurotoxicity 
of amyloid beta and alpha-synuclein oligomers [15, 45]. These oligomers bind to 
PrP residues 95–105 [46] and mediate activation of the signaling intermediate Fyn 
tyrosine kinase by mGluR5, which causes overactivation of NMDARs leading to 
excitotoxicity and cell death [15, 45]. Similarly, NMDAR is also overactivated by 
infectious and toxic PrPD species binding to membrane PrPC, likely through the 
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same mechanistic pathway as the oligomers of amyloid beta and alpha-synuclein, 
which subsequently activates the p38 Mitogen Activated Protein Kinase signal-
ing pathway and induces neurotoxicity [23]. The activation of these downstream 
signaling pathways significantly disrupts both the propagation of action potentials 
and synaptic functions leading to impairment of LTP and LTD [15, 23, 45, 47, 48]. 
Together, the evidence suggests that, indirectly, PrPC normally acts as an upstream 
modulator of a wide variety of intracellular signaling pathways that are essential for 
neuronal activity.
3. Neuro-physiology during prion diseases
Because the underlying mechanisms by which neuronal functions become 
impaired following the misfolding of PrPC to PrPD and the accumulation of PrPD 
remain largely unknown, studies have been focused on determining how the 
roles of PrPC in neuronal activity become altered during disease. However, these 
mechanisms may be influenced by how PrPC gets misfolded into PrPD. There are 
three etiologies of prion disease; exposure to infectious prions (acquired), familial 
disease-related mutations within prnp, or undergoing unknown cellular events that 
cause sporadic prion disease. To date, there has been no way to identify cells that 
might develop sporadic prion disease due to its unknown cause. However, the causes 
of acquired and genetic prion diseases can be identified, allowing these diseases to 
be modeled in the laboratory. These models of prion diseases have provided signifi-
cant insights to physiological changes in cells prior to clinical onsets.
During the clinical stage of either acquired or genetic prion diseases, significant 
degeneration of neurons has occurred, as well as the pathological features specific 
to prion diseases such as spongiosis, deposition of PrPD including the protease-
resistant species, and production of potent self-propagating PrPD [49–51]. The 
degeneration of neurons impedes studies attempting to further understand patho-
genic mechanisms during this stage of the disease for two main reasons. Firstly, 
the degeneration of neurons is almost solely responsible for all neuronal dysfunc-
tions at the clinical stage [51, 52]. Second, neuronal degeneration is irreversible; 
attempts to rescue mice that have already undergone neuronal degeneration only 
prolong the disease progression in the terminal stages to death [53]. In addition, 
recent studies have reported that at the clinical stage of CJD, the peripheral nerves 
are also severely demyelinated (Figure 1(6)) [54, 55], supporting that therapeutic 
drug interventions at this stage might be too late. Hence, studies have shifted 
interests toward understanding changes during the preclinical stage to early onset 
of clinical signs at which points the neurodegeneration is very minimal and thera-
peutic interventions have been successful in mice [56]. Since electrophysiological 
paradigms can detect neuronal dysfunctions during the asymptomatic stage as well 
as the early symptomatic stage, studies have utilized these paradigms to further 
understand molecular mechanisms that may lead to therapeutic development 
against neuronal degeneration.
3.1 Acquired prion diseases
When mice expressing endogenous PrPC are exposed to infectious PrPD, they 
will develop prion disease, usually over a well-defined (strain-specific) period of 
time [57, 58]. Hence, it is possible to study biochemical and physiological proper-
ties of mouse neuronal cells during the asymptomatic stage prior to the onset of 
clinical disease. The hippocampal CA1 LTP is significantly impaired in wild type 
mice infected with mouse-adapted scrapie (ME7) before the onset of clinical 
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signs (Figure 1(1)) [51, 59]. This impairment of LTP strongly correlates with 
the increased levels of synaptic PrPD [59]. A similar finding has been reported 
in hamsters infected with hamster-adapted scrapie PrPD (Sc237) [60]. The LTP 
dysfunction indicates an overall synaptic transmission abnormality (Figure 1). 
Because PrP regulates activities of various receptors in both pre- and postsynaptic 
terminals that are essential for the induction and maintenance of LTP, the disrup-
tion of LTP is likely a result of the functions of these receptors being altered during 
disease. From as early as 30 days post inoculation (dpi) in the neocortex layer five 
and 50 dpi in the hippocampal CA1, before the early onset of clinical disease (70–80 
dpi), the medium and late afterhyperpolarizations become significantly impaired 
(Figure 1(2)) [60]. This finding suggests a significant calcium dysregulation at 
this stage of the disease, which is believed to be due to a significant disruption of 
certain voltage-gated calcium channels such as those activated by potassium or 
from a significant failure of intracellular calcium storage systems to store or release 
calcium [60]. In addition, the activity of GABA(A) receptor is hindered in GPI−/− 
mice infected with scrapie during the early stage of the disease (Figure 1(3)) [61]. 
This finding appears consistent with the reports of the close interaction between 
GABA(A) receptor and PrPD across the disease progression as well as the increased 
GABA-like immunoreactivity in various brain regions of scrapie-infected hamsters 
Figure 1. 
Connections between the neuro-physiological changes during diseases pathogenesis and the loss or 
corruption of PrPC function. The neurons in the low magnification (top right side) are CNS neurons with 
normal myelin sheath. These neurons include two glutamatergic neurons (yellow) and one GABAergic neurons 
(blue) that form dendrodendritic synapses (as visualized in high magnification). The neuron at the bottom 
right corner is a peripheral nerve cell with demyelination. Relative to wild type mice expressing PrPC without 
the disease: 1—hippocampal LTP is impaired in mice lacking PrPC as well as in mice developing prion disease 
caused by infection; 2—the amplitudes of medium and slow afterhyperpolarizations (AHs) are reduced in PrP 
knockout (KO) mice and wild type mice during the early symptomatic stage of prion disease caused by exposure 
to infectious PrPD; 3—GABA(A) receptor currents are weak in PrP knockout mice as well as in disease caused 
by PrPD infection; 4—hippocampal CA1 metaplasiticity is abnormally enhanced in mice harboring the 
D178N/129V mutation and slightly enhanced in PrP knockout mice; 5—inward ion currents through cation-
permeable channels are abnormally increased in cells expressing P101L, G113V, and G130V; 6—peripheral 
nerve cells are demyelinated in both PrP knockout mice as well as in disease. 1–5—These dysfunctions are likely 
due to changes in activities of several key receptors/ion channels, known to interact with PrP, in excitatory 
(Glutamatergic) and inhibitory (GABAergic) neurons.
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starting from 21 dpi [62, 63]. The weak inhibitory activity of GABA(A) receptor 
may be associated with why seizure is common in prion disease.
Another way of studying the specific effects of exposure to toxic PrPD is 
through assessing the acute response of cells [5, 64]. A recent study has reported 
that acute exposure of ex vivo hippocampal slices to ex vivo mouse-adapted human 
prions (M1000 and MU02) disrupts CA1 LTP by causing dysfunctions of both pre- 
and postsynaptic activity [5]. With a similar approach, one study has reported that a 
24-hour exposure of a mouse-adapted scrapie (RML) to cultured primary neuronal 
cells from wild type mice causes reduction of spontaneous neuronal activity due to a 
substantial loss of dendritic spines [23, 64]. The data show that, prior to developing 
clinical prion disease, neuronal cells modeling acquired prion disease have already 
undergone substantial biochemical and physiological changes.
3.2 Genetic prion diseases
Genetic prion diseases have been modeled in mice as well as in cultured cells. 
Genetic prion diseases are caused by disease-related mutations in the prnp gene. 
These diseases are autosomal dominant, therefore only one copy of the mutant 
allele is required to cause disease. Using these models, cellular and physiological 
changes can be measured during the asymptomatic stage prior to the onset of clini-
cal signs, or before the misfolded PrPD becomes detectable [29, 65, 66]. Tg(PG14) 
mice, expressing a nine repeat insertion in the prion octapeptide region, display 
significant motor deficits prior to neuronal degeneration [65]. These early motor 
disturbances are associated with poor synaptic transmissions in cerebellar gluta-
matergic neurons due to a dysfunction in the mechanism that traffics and anchors 
voltage-gated calcium channels onto the cell membrane [65]. While the mecha-
nisms of these abnormalities are likely due to a loss of functional PrPC or corrup-
tion of normal PrPC roles, the peptide insertion may directly yield PrPD species 
that are neurotoxic, resembling the pathophysiological mechanism of other diseases 
with repeat insertion such as Huntington’s disease. Mouse models of familial CJD 
(Tg(CJD)) with the D178N mutation and a valine at codon 129, exhibit significant 
dysfunction of hippocampal CA1 LTP and metaplasticity during the presymptom-
atic stage (Figure 1(4)), which is approximately 50% of the disease progression, to 
the early onset of clinical disease [29, 66].
In cultured cells, expression of PrP P101L, a point mutant of mouse PrP that is 
equivalent to P102L mutation in GSS, significantly enhances inward currents and 
cell death despite a lack of insoluble PrPD (Figure 1(5)) [35, 36]. Similarly, cells 
expressing G113V or G130V mutations (models of genetic CJD and GSS) have mini-
mal levels of insoluble PrPD but display increased inward currents [35]. Based on 
the role of PrPC as a regulator of ion channel activity (as described previously), the 
enhanced inward currents are likely due to a loss of PrPC functionality. However, 
exogenous PrP mutant lacking residues 105–125 while containing the membrane 
anchor motif can directly mediate membrane pore formation that increases sodium 
and calcium inward currents [67]. This finding suggests that the PrP mutant 
directly mediates neurotoxicity. Consistently, one study has revealed that the 
introduction of nanomolar concentrations of an exogenous PrP mutant lacking the 
residues 106–126 to rat forebrain neurons enhances the neuronal excitability by 
disrupting the whole-cell outward potassium currents, including the currents of 
calcium-activated potassium channels, which subsequently impairs the inhibitory 
activity of GABA [68]. This finding is consistent with Tg(CJD) mice exhibiting 
high susceptibility to kainite-induced seizure [65], and the report of carriers of the 
E200K mutation displaying increased MRI cortical hyperintensity during the early 
onset of clinical disease [1]. Taken together, PrPD species in genetic prion diseases 
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appear to cause a significant dysfunction of inward and outward ion currents, 
which can disrupt the role of inhibitory neurons, thereby leading to enhanced 
neuronal excitability and consequently cell death.
4. Conclusions
PrPC plays a variety of essential roles in neuronal electrical signaling. PrPC 
maintains electrophysiological phenomena associated with cognition and behav-
iour by regulating ion channels activity, calcium homeostasis, inhibitory neuronal 
activity, various intracellular signal transduction pathways, and peripheral nerve 
myelination. These roles have been determined through two main experimental 
approaches including (1) knocking out of PrPC expression to completely abolish 
the roles of PrPC, and (2) deletion of specific PrP amino acid residues to change 
PrPC functions. Importantly, prior to the overt degeneration of neurons during 
the disease’s progression, some of the disease-related neuronal dysfunctions are 
very similar to the altered neuro-physiological properties evident when PrPC is 
abolished or mutated. The reduction of LTP, impaired medium and late afterhy-
perpolarizations, disrupted calcium homeostasis, and weak inhibitory activity of 
GABA(A)R (Figure 1), are evident in mice devoid of PrPC as well as in mice and 
rats at the stages (asymptomatic to early onset) of prion diseases caused by expo-
sure to infectious PrPD. In addition, the hyperactivity exhibited by neurons lacking 
the charged and hydrophobic residues of PrP is also evident in neurons of mice 
and cells harboring the disease-related mutants such as the D178N/129V and P101L 
(Figure 1). Further, some of the disease-related neuronal dysfunctions such as the 
reduction of LTP and spontaneous neuronal activity are evident in neuronal cells 
exposure to neurotoxic PrPD, which indicates that another way PrPC contributes 
to disease pathogenesis is by gaining a neurotoxic role. Overall, while the specific 
mechanisms of PrPC and PrPD engagement with the neuronal electrical signaling 
pathways remain to be elucidated, there are clear connections between the neuro-
physiological changes during diseases pathogenesis and the loss or corruption of 
PrPC function.
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